여드름 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약물 종류별, 투여 방법별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Acne Drugs Market Growth & Trends:

The global acne drugs market size is expected to reach USD 13.13 billion by 2030, according to a new report by Grand View Research, Inc., registering a 5.2% CAGR from 2024 to 2030. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

Acne Drugs Market Report Highlights:

• Inflammatory acne dominated the market and accounted for a share of 65.4% in 2023. The factors attributing to the growth of the segment are bacterial skin infections that can cause inflammatory acne.
• Over the counter (OTC) drugs dominated the market and accounted for a share of 35.9% in 2023.
• Topical segment dominated the market and accounted for a share of 47.5% in 2023. The segment growth can be attributed to rising demand for topical products due to their ease of use, accurate dosage, and high availability as an over-the-counter drug.
• Retail pharmacies dominated the market and accounted for a share of 37.5% in 2023.
• North America acne drugs market dominated the market in 2023. The acne drugs market growth is attributed to the rising prevalence of acne, developed healthcare infrastructure, and the strong presence of companies involved in the acne drugs market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Acne Drugs Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Acne Drugs Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Acne Drugs Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Acne Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Inflammatory Acne
  • 4.3.1. Inflammatory Acne Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Non-inflammatory Acne
  • 4.4.1. Non-inflammatory Acne Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acne Drugs Market: Therapeutic Class Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Acne Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Topical Retinoids
  • 5.3.1. Topical Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Oral Antibiotics
  • 5.4.1. Oral Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Oral Retinoids
  • 5.5.1. Oral Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Over the Counter (OTC) Drugs
  • 5.6.1. Over the Counter (OTC) Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acne Drugs Market: Mode of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Acne Drugs Market: Mode of Administration Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Topical
  • 6.3.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acne Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Acne Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
• 7.3. Hospital Pharmacies
  • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Online Pharmacies
  • 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acne Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Acne Drugs Market Share, By Region, 2023 & 2030, (USD Million)
• 8.2. North America
  • 8.2.1. North America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. France Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. China
    • 8.4.2.1. China Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Japan Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. India Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Australia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Saudi Arabia
    • 8.6.2.1. Saudi Arabia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. UAE
    • 8.6.3.1. UAE Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. South Africa
    • 8.6.4.1. South Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. GALDERMA
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/ Strategic Initiatives
  • 9.4.2. Johnson & Johnson Services, Inc.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/ Strategic Initiatives
  • 9.4.3. GSK plc.
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/ Strategic Initiatives
  • 9.4.4. Pfizer Inc.
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/ Strategic Initiatives
  • 9.4.5. AbbVie Inc.
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/ Strategic Initiatives
  • 9.4.6. Sun Pharmaceutical Industries Ltd.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/ Strategic Initiatives
  • 9.4.7. Bausch Health Companies Inc.
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/ Strategic Initiatives
  • 9.4.8. Nestle Skin Health S.A.
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/ Strategic Initiatives
  • 9.4.9. Bayer AG
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/ Strategic Initiatives
  • 9.4.10. Viatris Inc.
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/ Strategic Initiatives
  • 9.4.11. Teva Pharmaceutical Industries Ltd.
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments/ Strategic Initiatives
  • 9.4.12. F. Hoffmann-La Roche Ltd
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments/ Strategic Initiatives
  • 9.4.13. LEO Pharma A/S
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments/ Strategic Initiatives
  • 9.4.14. Perrigo Company plc
    • 9.4.14.1. Participant's Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Recent Developments/ Strategic Initiatives